Sophia Genetics Reaches Milestone to Become the Global Leader in Precision Medicine, Connecting Over 100 Hospitals and Laboratories to form the World's Largest Clinical Genomics Community for Molecular Diagnosis

CAMBRIDGE, England, November 25, 2015 /PRNewswire/ --

• Sophia Genetics has risen to become the global leader in precision medicine, now supporting over 100 healthcare institutions around the world to form the world's largest clinical genomics community
• Backed by Invoke Capital, Sophia's platform, Sophia DDM™, is a software-as-a-service platform designed to perform routine diagnostic testing, with an emphasis on genomic analysis and machine learning to help clinicians more quickly and accurately diagnose some common cancers and inherited conditions
• Since its launch in April 2014, Sophia's cutting edge platform has supported the diagnosis of over 25,000 patients in Europe and 80,000 patients are expected to benefit in 2016

Sophia Genetics, the global leader in Data Driven Medicine (DDM), announced today that its platform, Sophia DDM™, now hosts the world's largest clinical genomics community for molecular diagnosis, placing Europe ahead of the US in precision medicine. Witnessing a 400% growth rate this year alone, it now supports over 100 institutions across 18 countries, rising to become the largest network globally for sharing knowledge and interpreting clinical genomics data.

All 100 plus institutions within the community use Sophia Genetic's cutting edge analytical solution and its advanced machine learning algorithms to analyse the genetic make-up of some common cancers and inherited conditions, such as such as cystic fibrosis, so that clinicians can more accurately diagnose patients at speed and at scale.

Speaking about this key milestone moment, Jurgi Camblong, CEO and co-founder of Sophia Genetics commented: "Over the past 18 months, Sophia Genetics' technology has been able to make precision medicine a reality for healthcare institutions across Europe, helping patients benefit from faster and more accurate diagnosis. I am thrilled that Sophia Genetics today has been recognised as the global leader in this field, and is helping Europe lead the wider healthcare industry in delivering the value and promises associated with personalised medicine."

Within the UK, Oxford University Hospital, Newcastle Medical Genetics, Aberdeen Medical Genetics, Liverpool Women's NHS Foundation Trust and NewGene leverage Sophia Genetics' industry-leading genetic analysis technology to provide clinicians the most accurate, fast and cost-effective means to offer genomic analysis of samples to their patients.

Since its inception, Sophia has built an innovative network of pioneer healthcare institutions. The community now spans 18 European countries from Spain to Poland, and places Europe as a leader in precision medicine. More countries are expected to join as new hospitals and labs make use of Sophia DDM™.

About Sophia Genetics 

Sophia Genetics, a European leader in Data Driven Medicine, brings together expertise in genetics, bioinformatics, machine learning and genomic privacy. Based in Switzerland, we are known for our high medical standards and Swiss precision when it comes to accuracy and quality management. Sophia Genetics offers health professionals who perform clinical genetic testing bioinformatics analysis, quality assurance, and secure banking of patient DNA sequence data generated by NGS. Sophia Genetics does not hold personal information on patients, and the patient data we do hold is anonymised. Sophia Genetics helps clinical laboratories to reduce the cost, overcome complexity and fulfil quality constraints related to the use of NGS in the clinic. For more information, visit http://www.sophiagenetics.com and follow @SophiaGenetics and @JurgiCamblong.